Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
Darren K. McGuire, Weichung Shih, Francesco Cosentino, et al.
JAMA Cardiology (2020) Vol. 6, Iss. 2, pp. 148-148
Open Access | Times Cited: 880

Showing 1-25 of 880 citing articles:

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh, Marco Metra, Marianna Adamo, et al.
European Heart Journal (2021) Vol. 42, Iss. 36, pp. 3599-3726
Open Access | Times Cited: 8685
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Paul A. Heidenreich, Biykem Bozkurt, David Aguilar, et al.
Circulation (2022) Vol. 145, Iss. 18
Open Access | Times Cited: 3031
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Paul A. Heidenreich, Biykem Bozkurt, David Aguilar, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 17, pp. e263-e421
Open Access | Times Cited: 1516
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa McDonagh, Marco Metra, Marianna Adamo, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 1, pp. 4-131
Open Access | Times Cited: 1508
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2753-2786
Open Access | Times Cited: 1145
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
A. Michael Lincoff, Kirstine Brown‐Frandsen, Helen M. Colhoun, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 24, pp. 2221-2232
Open Access | Times Cited: 1034
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Naveed Sattar, Matthew M.Y. Lee, Søren Lund Kristensen, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 10, pp. 653-662
Open Access | Times Cited: 934
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Peter Rossing, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2022) Vol. 102, Iss. 5, pp. S1-S127
Open Access | Times Cited: 702
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
Nikolaus Marx, Massimo Federici, Katharina Schütt, et al.
European Heart Journal (2023) Vol. 44, Iss. 39, pp. 4043-4140
Open Access | Times Cited: 680
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetologia (2022) Vol. 65, Iss. 12, pp. 1925-1966
Open Access | Times Cited: 670
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
Muthiah Vaduganathan, Kieran F. Docherty, Brian Claggett, et al.
The Lancet (2022) Vol. 400, Iss. 10354, pp. 757-767
Open Access | Times Cited: 618
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Circulation (2023) Vol. 148, Iss. 9
Open Access | Times Cited: 557
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
Bertram Pitt, Jingmei Li, Rajiv Agarwal, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 24, pp. 2252-2263
Open Access | Times Cited: 446
2024 ESC Guidelines for the management of chronic coronary syndromes
Christiaan Vrints, Felicita Andreotti, Konstantinos C. Koskinas, et al.
European Heart Journal (2024) Vol. 45, Iss. 36, pp. 3415-3537
Open Access | Times Cited: 440
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Mengwei Li, Xiaowei Chi, Ying Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 405
Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association
Chiadi E. Ndumele, Janani Rangaswami, Sheryl L. Chow, et al.
Circulation (2023) Vol. 148, Iss. 20, pp. 1606-1635
Open Access | Times Cited: 369
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
Ildiko Lingvay, Priya Sumithran, Ricardo V. Cohen, et al.
The Lancet (2021) Vol. 399, Iss. 10322, pp. 394-405
Closed Access | Times Cited: 368
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. S158-S190
Open Access | Times Cited: 327
Emerging Targets in Type 2 Diabetes and Diabetic Complications
Sevgican Demir, Peter P. Nawroth, Stephan Herzig, et al.
Advanced Science (2021) Vol. 8, Iss. 18
Open Access | Times Cited: 318
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Lawrence Blonde, Guillermo E. Umpierrez, Sarah Reddy, et al.
Endocrine Practice (2022) Vol. 28, Iss. 10, pp. 923-1049
Open Access | Times Cited: 315
A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association
Chiadi E. Ndumele, Ian J. Neeland, Katherine R. Tuttle, et al.
Circulation (2023) Vol. 148, Iss. 20, pp. 1636-1664
Open Access | Times Cited: 226
Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease
Francesco Cosentino, Christopher P. Cannon, David Z.I. Cherney, et al.
Circulation (2020) Vol. 142, Iss. 23, pp. 2205-2215
Open Access | Times Cited: 211
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 9, pp. 833-955
Open Access | Times Cited: 211
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
Javed Butler, Milton Packer, Gerasimos Filippatos, et al.
European Heart Journal (2021) Vol. 43, Iss. 5, pp. 416-424
Open Access | Times Cited: 207
American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update
Susan L. Samson, Priyathama Vellanki, Lawrence Blonde, et al.
Endocrine Practice (2023) Vol. 29, Iss. 5, pp. 305-340
Open Access | Times Cited: 203
Page 1 - Next Page

Scroll to top